title: Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
abstract: BACKGROUND
  Single-nucleotide polymorphisms in apoptosis-related genes have been shown to play a role in the efficacy of platinum-based chemotherapy and may influence clinical outcomes. Our study aimed to evaluate the correlations of four functional single-nucleotide polymorphisms - FAS -670 A>G, FAS ligand -844 T>C, survivin -31 G>C, and survivin 9386 C>T - with drug response and clinical outcomes in advanced non-small-cell lung cancer patients who received platinum-based chemotherapy.
  
  
  METHODS
  Polymorphisms were evaluated using the polymerase chain reaction-based restriction fragment-length polymorphism technique.
  
  
  RESULTS
  Patients with the CC genotype of FAS -670 A>G had worse overall survival (OS) than those with the CT or TT genotype (P=0.044), with median OS values of 20.1 months, 22.8 months, and 26.0 months, respectively. Furthermore, progression-free survival was associated with the FAS -670 A>G polymorphism (P=0.032). In addition, patients with the TC and CC genotypes of survivin 9386 C>T experienced improved survival compared with patients with the TT genotype (median OS 31.4 months and 22.8 months, respectively).
  
  
  CONCLUSIONS
  The functional FAS -670 A>G and survivin 9386 C>T polymorphisms are potential independent prognostic factors in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
authors.affiliation: Department of Thoracic Surgery, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, People's Republic of China.
authors.forename: Kai-Yi
authors.initials: KY
authors.lastname: Tao
authors.affiliation: Department of Radiology, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, People's Republic of China.
authors.forename: Xian-Xing
authors.initials: XX
authors.lastname: Li
authors.affiliation: Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, People's Republic of China.
authors.forename: Wei-Zhen
authors.initials: WZ
authors.lastname: Xu
authors.affiliation: Physical Examination Center, Zhejiang Provincial People's Hospital, Hangzhou, People's Republic of China.
authors.forename: Yin
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Radio-Chemotherapy Oncology, Lishui People's Hospital, Sixth Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
authors.forename: Shuang-Mei
authors.initials: SM
authors.lastname: Zhu
authors.affiliation: Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, People's Republic of China.
authors.forename: Hua-Xia
authors.initials: HX
authors.lastname: Xie
authors.affiliation: Department of Radio-Chemotherapy Oncology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China.
authors.forename: Wen-Hua
authors.initials: WH
authors.lastname: Luo
authors.affiliation: Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
authors.forename: Yan-Jun
authors.initials: YJ
authors.lastname: Xu
authors.affiliation: Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Zhejiang Cancer Hospital (Zhejiang Cancer Research Institute), Hangzhou, People's Republic of China ; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Xu
keywords: FAS −670 A>G; chemotherapy response; lung cancer; polymorphism; survivin 9386 C>T